Compositions for altering cyclic adp-ribose secondary messenger signalling
AssigneesYeda Research and Development Co. Ltd., Dana-Farber Cancer Institute, Inc.
InventorsRotem SOREK, Gil AMITAI, Azita LEAVITT, Erez YIRMIYA, Philip J. KRANZUSCH, Allen LU, Samuel J. HOBBS
Life of this patent
Estimating the term…
Abstract
Methods of treating a disease or disorder associated with a down or up-regulation of an immune response of a subject are disclosed. The methods comprising administering to the subject a therapeutically effective amount of any one or more of the molecule 1′-2′ glycosyl cyclic adenosine diphosphate ribose (1′-2′ gcADPR), 1′-3′ gcADPR or Tad1 protein.
Claims10
A method of treating a disease or disorder associated with a down-regulation of an immune response of a subject comprising administering to the subject a therapeutically effective amount of a gcAPDR molecule, thereby treating the disease or disorder associated with a down-regulation of an immune response of a subject, wherein said gcAPDR molecule comprises at least one of 1′-2′ glycosyl cyclic adenosine diphosphate ribose (1′-2′ gcADPR) and/or 1′-3′ glycosyl cyclic adenosine diphosphate ribose (1′-3′ gcADPR), or a salt, an enantiomer, solvate or hydrate thereof.
An article of manufacture comprising:
- (i) 1′-2′ gcADPR and/or 1′-3′ gcADPR, or a salt, an enantiomer, solvate or hydrate thereof;
- and
- (ii) an antibody directed against an immune checkpoint protein.
A vaccine comprising a disease associated antigen and an adjuvant comprising 1′-2′ gcADPR and/or 1′-3′ gcADPR. or a salt, an enantiomer, solvate or hydrate thereof.
Dependencies are inferred from the claim text.